Difference between revisions of "Aop:39"
(29 intermediate revisions by 4 users not shown) | |||
Line 1: | Line 1: | ||
− | |||
__NOTOC__ | __NOTOC__ | ||
+ | = Status = | ||
+ | <span style="color:#FF0000"> | ||
+ | This is a legacy representation of this AOP. Please see the current version here: | ||
− | + | [//{{SERVERNAME}}/aops/39 https://{{SERVERNAME}}/aops/39] | |
− | < | + | </span> |
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | |||
− | |||
− | |||
− | + | == AOP Title == | |
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | < | + | <div class='Title'> Sensitisation of the Respiratory Tract induced by Covalent Binding of Low Molecular Weight Organic Chemicals to Proteins </div> |
− | + | ||
− | < | + | <div id='shortTitle' class='Title2'>Short name: Respiratory Sensitisation/Allergy induced by covalent binding to proteins </div> |
− | < | + | |
− | + | == Authors == | |
− | + | ||
− | + | Kristie Sullivan, Physicians Committee for Responsible Medicine/ICAPO, Ksullivan@pcrm.org | |
− | + | ||
+ | Darrell Boverhof, Dow Chemical Company | ||
+ | |||
+ | Stella Cochrane, Unilever | ||
+ | |||
+ | Steven Enoch, Liverpool John Moores University | ||
+ | |||
+ | Janine Ezendam, RIVM | ||
+ | |||
+ | Ian Kimber, University of Manchester | ||
+ | |||
+ | Joanna Matheson & Kent Carlson, US CPSC | ||
+ | |||
+ | Grace Patlewicz, DuPont | ||
+ | |||
+ | Erwin Roggen, Novozymes | ||
+ | |||
+ | Katherina Sewald, Fraunhofer ITEM | ||
− | |||
== Status == | == Status == | ||
+ | |||
+ | '''Please follow the link to [//{{SERVERNAME}}/aops/{{PAGENAMEE}}/snapshots snapshots page] to view and create Snapshots of this AOP.''' | ||
+ | |||
+ | '''Alert: The Weight of Evidence column in the Molecular Initiating Event and Key Event tables has changed to Essentiality. Consider re-evaluating the columns in these tables.''' | ||
+ | |||
+ | '''OECD Project 1.20:''' The Adverse Outcome Pathway for Sensitisation of the Respiratory Tract Induced by Covalent Binding to Proteins | ||
+ | |||
'''Under development: Do not distribute or cite.''' | '''Under development: Do not distribute or cite.''' | ||
− | == | + | This AOP page was last modified on {{REVISIONMONTH1}}/{{REVISIONDAY}}/{{REVISIONYEAR}}. |
+ | |||
+ | <span id='ToggleRevision' style="text-decoration: underline;">Click here to show/hide revision dates for related pages</span> | ||
+ | {|class="wikitable sortable" id="Revtable" | ||
+ | |||
+ | !Page | ||
+ | !Revision Date/Time | ||
+ | |||
+ | |- | ||
+ | |||
+ | |} | ||
+ | |||
+ | == Abstract == | ||
+ | The assessment of xenobiotics for potential to induce an allergenic response in the respiratory tract is of great regulatory and industrial interest. Currently, however, there are not standardized, validated and accepted regulatory models for detecting these materials, potentially due to remaining uncertainty within the literature as to the exact mechanistic pathway leading to respiratory allergy. | ||
+ | |||
+ | Ongoing work in this area has hypothesized some differences between the dermal and respiratory sensitisation pathways; however in some cases a lack of strong empirical evidence on a variety of chemistries to test these hypothesis. This AOP represents the currently available data with the aim of identifying knowledge gaps which may be filled with directed research. | ||
== Summary of the AOP == | == Summary of the AOP == | ||
[[Category:Adverse Outcome Pathway]] | [[Category:Adverse Outcome Pathway]] | ||
+ | Please follow link to [//{{SERVERNAME}}/aops/{{PAGENAMEE}} widget page] to edit this section. | ||
+ | |||
+ | <span style="color:#FF0000">'''If you manually enter text in this section, it will get automatically altered or deleted in subsequent edits using the widgets.'''</span> | ||
=== Molecular Initiating Event === | === Molecular Initiating Event === | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
{|class="wikitable sortable" id="MIEproof" | {|class="wikitable sortable" id="MIEproof" | ||
!Molecular Initiating Event | !Molecular Initiating Event | ||
− | ! | + | !Support for Essentiality |
|- | |- | ||
− | |[[Covalent binding to | + | |[[Event:75|Covalent binding to protein, possibly lysine residue, N/A]]||[[Aop:39#Essentiality of the Key Events|Strong]] |
|- | |- | ||
Line 91: | Line 86: | ||
=== Key Events === | === Key Events === | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
{|class="wikitable sortable" id="KEproof" | {|class="wikitable sortable" id="KEproof" | ||
!Event | !Event | ||
− | ! | + | !Support for Essentiality |
+ | |||
+ | |- | ||
+ | |||
+ | |[[Event:151|Inflammatory cytokines, chemokines, cytoprotective gene pathways, Activation]]||[[Aop:39#Essentiality of the Key Events|Moderate]] | ||
|- | |- | ||
Line 133: | Line 101: | ||
=== Adverse Outcome === | === Adverse Outcome === | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
{|class="wikitable sortable" id="AOproof" | {|class="wikitable sortable" id="AOproof" | ||
!Adverse Outcome | !Adverse Outcome | ||
− | |||
|- | |- | ||
− | |[[ | + | |[[Event:313|Allergic Respiratory Hypersensitivity Response, Increase]] |
|- | |- | ||
Line 179: | Line 115: | ||
=== Relationships Among Key Events and the Adverse Outcome === | === Relationships Among Key Events and the Adverse Outcome === | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
{| class="wikitable sortable" id="relation" | {| class="wikitable sortable" id="relation" | ||
− | |||
!Event | !Event | ||
!Description | !Description | ||
!Triggers | !Triggers | ||
!Weight of Evidence | !Weight of Evidence | ||
+ | !Quantitative Understanding | ||
+ | |||
+ | |- | ||
+ | |||
+ | |[[Event:75|Covalent binding to protein, possibly lysine residue, N/A]]||[[Relationship:88|Directly Leads to]]||[[Event:151|Inflammatory cytokines, chemokines, cytoprotective gene pathways, Activation]]||[[Relationship:88#Weight of Evidence|Moderate]]||[[Relationship:88#Quantitative Understanding of the Linkage|Weak]] | ||
|- | |- | ||
|} | |} | ||
+ | |||
+ | === Network View === | ||
+ | <div id="cytoscapeweb"> | ||
+ | Cytoscape Web will replace the contents of this div with your graph. | ||
+ | </div> | ||
+ | <div id="note"> | ||
+ | <p>Click nodes or edges.</p> | ||
+ | </div> | ||
=== Life Stage Applicability === | === Life Stage Applicability === | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
{|class="wikitable sortable" id="LSproof" | {|class="wikitable sortable" id="LSproof" | ||
Line 276: | Line 152: | ||
=== Taxonomic Applicability === | === Taxonomic Applicability === | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
{|class="wikitable sortable" id="Specproof" | {|class="wikitable sortable" id="Specproof" | ||
Line 330: | Line 166: | ||
=== Sex Applicability === | === Sex Applicability === | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
{|class="wikitable sortable" id="Sexproof" | {|class="wikitable sortable" id="Sexproof" | ||
Line 368: | Line 178: | ||
=== Graphical Representation === | === Graphical Representation === | ||
− | *[ | + | *[https://aopkb.org/common/AOP_Graphic_Template2.pptx Click to download template for graphical representation] |
[[File:Respiratory Sensitisation/Allergy induced by covalent binding to proteins.jpg | 900px | Click to upload graphical representation]] | [[File:Respiratory Sensitisation/Allergy induced by covalent binding to proteins.jpg | 900px | Click to upload graphical representation]] | ||
− | == Assessment of the AOP == | + | == Overall Assessment of the AOP == |
<em> | <em> | ||
Consider the following criteria (may include references to KE Relationship pages): | Consider the following criteria (may include references to KE Relationship pages): | ||
Line 385: | Line 195: | ||
</em> | </em> | ||
− | == | + | ===Weight of Evidence Summary=== |
+ | [[#Relationships Among Key Events and the Adverse Outcome | Summary Table]]<br> | ||
+ | <em> | ||
+ | Provide an overall summary of the weight of evidence based on the evaluations of the individual linkages from the Key Event Relationship pages. | ||
+ | </em> | ||
+ | |||
+ | ===Essentiality of the Key Events=== | ||
+ | [[#Molecular Initiating Event | Molecular Initiating Event Summary]], | ||
+ | [[#Key Events | Key Event Summary]]<br> | ||
+ | <em> | ||
+ | Provide an overall assessment of the essentiality for the key events in the AOP. Support calls for individual key events can be included in the molecular initiating event, key event, and adverse outcome tables above. | ||
+ | </em> | ||
+ | |||
+ | ===Quantitative Considerations=== | ||
+ | [[#Relationships Among Key Events and the Adverse Outcome | Summary Table]]<br> | ||
+ | <em> | ||
+ | Provide an overall discussion of the quantitative information available for this AOP. Support calls for the individual relationships can be included in the Key Event Relationship table above. | ||
+ | </em> | ||
+ | |||
+ | ===Applicability of the AOP=== | ||
+ | [[#Life Stage Applicability | Life Stage Applicability]], | ||
+ | [[#Taxonomic Applicability | Taxonomic Applicability]], | ||
+ | [[#Sex Applicability | Sex Applicability]]<br> | ||
<em> | <em> | ||
Elaborate on the domains of applicability listed in the summary section above. Specifically, provide the literature supporting, or excluding, certain domains. | Elaborate on the domains of applicability listed in the summary section above. Specifically, provide the literature supporting, or excluding, certain domains. | ||
</em> | </em> | ||
+ | |||
+ | == Considerations for Potential Applications of the AOP (optional) == | ||
== References == | == References == | ||
<references /> | <references /> | ||
+ | Chipenda I, Hettick JM, Siegal PD (2011) Haptenation: Chemical Reactivity and Protein Binding, Journal of Allergy, vol. 2011, Article ID 839682, 11 pages. doi:10.1155/2011/839682. | ||
+ | |||
+ | Templeton D (2004) Mechanisms of Immunosensitisation to Metals, Pure and Applied Chemistry, 76:1255-1268. | ||
+ | == Confidence in the AOP == | ||
+ | <span style="color:red; margin:30px; font-weigth:900; font-size: 200%" >Information from this section should be moved to the Key Event Relationship pages!<br><br></span> | ||
+ | <em> | ||
+ | Elaborate on the domains of applicability listed in the summary section above. Specifically, provide the literature supporting, or excluding, certain domains. | ||
+ | </em> | ||
+ | |||
+ | Sensitizers which do not fit into this AOP: | ||
+ | |||
+ | There have been a number of studies into the sensitisation (and toxicity) of transition metal complexes; key amongst these is a recent study outlining the evidence for these complexes initiating sensitisation via the formation of co-ordination complexes rather than covalent bond formation (Chipenda et al 2011). The authors of this study present the evidence that these co-ordination complexes are not stable enough to survive the antigen processing that a covalent hapten undergoes, thus cannot sensitise via this MIE. Instead an alternative MIE is outlined in which these complexes bind to cell surface proteins like MHC, bypassing the intracellular antigen process. This MIE fits in with the observed cross-reactivity that appears to transcend the trends one would expect based on the periodic table (for example, complexes of Cr, a group 6 metal, cross sensitising with complexes of Co, a group 9 metal) (Templeton et al 2004). It is thought that the surface protein chelates the metal complex and presents it to T-cells directly. Therefore transition metals would require a separate AOP from chemicals acting via covalent binding to proteins. |
Latest revision as of 18:52, 11 December 2016
Status
This is a legacy representation of this AOP. Please see the current version here:
AOP Title
Authors
Kristie Sullivan, Physicians Committee for Responsible Medicine/ICAPO, Ksullivan@pcrm.org
Darrell Boverhof, Dow Chemical Company
Stella Cochrane, Unilever
Steven Enoch, Liverpool John Moores University
Janine Ezendam, RIVM
Ian Kimber, University of Manchester
Joanna Matheson & Kent Carlson, US CPSC
Grace Patlewicz, DuPont
Erwin Roggen, Novozymes
Katherina Sewald, Fraunhofer ITEM
Status
Please follow the link to snapshots page to view and create Snapshots of this AOP.
Alert: The Weight of Evidence column in the Molecular Initiating Event and Key Event tables has changed to Essentiality. Consider re-evaluating the columns in these tables.
OECD Project 1.20: The Adverse Outcome Pathway for Sensitisation of the Respiratory Tract Induced by Covalent Binding to Proteins
Under development: Do not distribute or cite.
This AOP page was last modified on 12/11/2016.
Click here to show/hide revision dates for related pages
Page | Revision Date/Time |
---|
Abstract
The assessment of xenobiotics for potential to induce an allergenic response in the respiratory tract is of great regulatory and industrial interest. Currently, however, there are not standardized, validated and accepted regulatory models for detecting these materials, potentially due to remaining uncertainty within the literature as to the exact mechanistic pathway leading to respiratory allergy.
Ongoing work in this area has hypothesized some differences between the dermal and respiratory sensitisation pathways; however in some cases a lack of strong empirical evidence on a variety of chemistries to test these hypothesis. This AOP represents the currently available data with the aim of identifying knowledge gaps which may be filled with directed research.
Summary of the AOP
Please follow link to widget page to edit this section.
If you manually enter text in this section, it will get automatically altered or deleted in subsequent edits using the widgets.
Molecular Initiating Event
Molecular Initiating Event | Support for Essentiality |
---|---|
Covalent binding to protein, possibly lysine residue, N/A | Strong |
Key Events
Event | Support for Essentiality |
---|---|
Inflammatory cytokines, chemokines, cytoprotective gene pathways, Activation | Moderate |
Adverse Outcome
Adverse Outcome |
---|
Allergic Respiratory Hypersensitivity Response, Increase |
Relationships Among Key Events and the Adverse Outcome
Event | Description | Triggers | Weight of Evidence | Quantitative Understanding |
---|---|---|---|---|
Covalent binding to protein, possibly lysine residue, N/A | Directly Leads to | Inflammatory cytokines, chemokines, cytoprotective gene pathways, Activation | Moderate | Weak |
Network View
Cytoscape Web will replace the contents of this div with your graph.
Click nodes or edges.
Life Stage Applicability
Life Stage | Evidence | Links |
---|
Taxonomic Applicability
Name | Scientific Name | Evidence | Links |
---|
Sex Applicability
Sex | Evidence | Links |
---|
Graphical Representation
Click to upload graphical representation
Overall Assessment of the AOP
Consider the following criteria (may include references to KE Relationship pages): 1. concordance of dose-response relationships; 2. temporal concordance among the key events and adverse effect; 3. strength, consistency, and specificity of association of adverse effect and initiating event; 4. biological plausibility, coherence, and consistency of the experimental evidence; 5. alternative mechanisms that logically present themselves and the extent to which they may distract from the postulated AOP. It should be noted that alternative mechanisms of action, if supported, require a separate AOP; 6. uncertainties, inconsistencies and data gaps.
Weight of Evidence Summary
Summary Table
Provide an overall summary of the weight of evidence based on the evaluations of the individual linkages from the Key Event Relationship pages.
Essentiality of the Key Events
Molecular Initiating Event Summary,
Key Event Summary
Provide an overall assessment of the essentiality for the key events in the AOP. Support calls for individual key events can be included in the molecular initiating event, key event, and adverse outcome tables above.
Quantitative Considerations
Summary Table
Provide an overall discussion of the quantitative information available for this AOP. Support calls for the individual relationships can be included in the Key Event Relationship table above.
Applicability of the AOP
Life Stage Applicability,
Taxonomic Applicability,
Sex Applicability
Elaborate on the domains of applicability listed in the summary section above. Specifically, provide the literature supporting, or excluding, certain domains.
Considerations for Potential Applications of the AOP (optional)
References
Chipenda I, Hettick JM, Siegal PD (2011) Haptenation: Chemical Reactivity and Protein Binding, Journal of Allergy, vol. 2011, Article ID 839682, 11 pages. doi:10.1155/2011/839682.
Templeton D (2004) Mechanisms of Immunosensitisation to Metals, Pure and Applied Chemistry, 76:1255-1268.
Confidence in the AOP
Information from this section should be moved to the Key Event Relationship pages!
Elaborate on the domains of applicability listed in the summary section above. Specifically, provide the literature supporting, or excluding, certain domains.
Sensitizers which do not fit into this AOP:
There have been a number of studies into the sensitisation (and toxicity) of transition metal complexes; key amongst these is a recent study outlining the evidence for these complexes initiating sensitisation via the formation of co-ordination complexes rather than covalent bond formation (Chipenda et al 2011). The authors of this study present the evidence that these co-ordination complexes are not stable enough to survive the antigen processing that a covalent hapten undergoes, thus cannot sensitise via this MIE. Instead an alternative MIE is outlined in which these complexes bind to cell surface proteins like MHC, bypassing the intracellular antigen process. This MIE fits in with the observed cross-reactivity that appears to transcend the trends one would expect based on the periodic table (for example, complexes of Cr, a group 6 metal, cross sensitising with complexes of Co, a group 9 metal) (Templeton et al 2004). It is thought that the surface protein chelates the metal complex and presents it to T-cells directly. Therefore transition metals would require a separate AOP from chemicals acting via covalent binding to proteins.